Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M M Regan

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IXS Aebi, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancerP Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)L Malorni, S Tyekucheva, A Gombos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2011
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IXS Aebi, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancerP Karlsson, Z Sun, D Braun, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2017
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trialA Gennari, Z Sun, U Hasler-Strub, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 18, 2025
Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)L Malorni, S Tyekucheva, A Gombos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen SubstudyG Jerusalem, S Farah, A Courtois, et al.
Pageof 5